| Q37694755 | Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates |
| Q28473451 | Drug-class specific impact of antivirals on the reproductive capacity of HIV |
| Q28478993 | HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection |
| Q34658079 | Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism |
| Q64235564 | Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis |
| Q36188725 | Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates |
| Q37126494 | Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1. |
| Q28547109 | Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings |
| Q28481276 | Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection |
| Q28088352 | Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q35598505 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. |